Tags

Type your tag names separated by a space and hit enter

An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria.
Expert Rev Clin Immunol. 2012 Jan; 8(1):33-41.ER

Abstract

Currently available second-generation H1-antihistamines include a wide group of drugs with a better therapeutic index (or risk-benefit ratio) than the classic antihistamines, although their properties and safety profiles may differ. Bilastine is a newly registered H1-antihistamine for the oral treatment of allergic rhinitis and urticaria, with established antihistaminic and antiallergic properties. Clinical studies in allergic rhinitis and chronic urticaria show that once-daily treatment with bilastine 20 mg is effective in managing symptoms and improving patient's quality of life, with at least comparable efficacy to other nonsedative H1-antihistamines. As far as studies in healthy volunteers, clinical assays and clinical experience can establish, bilastine's safety profile is satisfactory, since it lacks anticholinergic effects, does not impair psychomotor performance or actual driving, and appears to be entirely free from cardiovascular effects.

Authors+Show Affiliations

Servicio de Alergia-Hospital de Basurto, Avenida de Montevideo, 18-48013 Bilbao, Spain. ignacio.jaureguipresa@osakidetza.netNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22149338

Citation

Jáuregui, Ignacio, et al. "An Overview of the Novel H1-antihistamine Bilastine in Allergic Rhinitis and Urticaria." Expert Review of Clinical Immunology, vol. 8, no. 1, 2012, pp. 33-41.
Jáuregui I, García-Lirio E, Soriano AM, et al. An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria. Expert Rev Clin Immunol. 2012;8(1):33-41.
Jáuregui, I., García-Lirio, E., Soriano, A. M., Gamboa, P. M., & Antépara, I. (2012). An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria. Expert Review of Clinical Immunology, 8(1), 33-41. https://doi.org/10.1586/eci.11.87
Jáuregui I, et al. An Overview of the Novel H1-antihistamine Bilastine in Allergic Rhinitis and Urticaria. Expert Rev Clin Immunol. 2012;8(1):33-41. PubMed PMID: 22149338.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria. AU - Jáuregui,Ignacio, AU - García-Lirio,Eduardo, AU - Soriano,Ana María, AU - Gamboa,Pedro M, AU - Antépara,Ignacio, PY - 2011/12/14/entrez PY - 2011/12/14/pubmed PY - 2012/4/4/medline SP - 33 EP - 41 JF - Expert review of clinical immunology JO - Expert Rev Clin Immunol VL - 8 IS - 1 N2 - Currently available second-generation H1-antihistamines include a wide group of drugs with a better therapeutic index (or risk-benefit ratio) than the classic antihistamines, although their properties and safety profiles may differ. Bilastine is a newly registered H1-antihistamine for the oral treatment of allergic rhinitis and urticaria, with established antihistaminic and antiallergic properties. Clinical studies in allergic rhinitis and chronic urticaria show that once-daily treatment with bilastine 20 mg is effective in managing symptoms and improving patient's quality of life, with at least comparable efficacy to other nonsedative H1-antihistamines. As far as studies in healthy volunteers, clinical assays and clinical experience can establish, bilastine's safety profile is satisfactory, since it lacks anticholinergic effects, does not impair psychomotor performance or actual driving, and appears to be entirely free from cardiovascular effects. SN - 1744-8409 UR - https://www.unboundmedicine.com/medline/citation/22149338/An_overview_of_the_novel_H1_antihistamine_bilastine_in_allergic_rhinitis_and_urticaria_ DB - PRIME DP - Unbound Medicine ER -